Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849843 | 0.89 | CA12 (0.49) | ALDH1A1TSHRHPGDPOLBMAPT | |
| SCHEMBL12799320 | 0.84 | CTSK (0.61) | ALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL2855929 | 0.81 | CA12 (0.59) | TSHRMAPT | |
| SCHEMBL2851881 | 0.78 | CA12 (0.41) | HPGDMAPTLMNA | |
| SCHEMBL2863206 | 0.76 | KMT2A (0.50) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL2865610 | 0.76 | CA12 (0.47) | ALDH1A1TSHRHPGDPOLBLMNA | |
| SCHEMBL2857193 | 0.75 | CA12 (0.46) | ALDH1A1TSHRHPGDPOLBLMNA | |
| SCHEMBL2857329 | 0.75 | ANPEP (0.48) | ALDH1A1POLB | |
| SCHEMBL2858022 | 0.75 | CA12 (0.49) | ALDH1A1HPGDPOLB | |
| SCHEMBL2857323 | 0.74 | CA12 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | claimed |
| EP-1963277-B1 | FLUORINATED COMPOUNDS | NPS PHARMA INC (US) | 2010-01-20 | — | — | EP | claimed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | claimed |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450336-B2 | Use of D-serine derivatives for the treatment of anxiety disorders | NPS PHARMACEUTICALS, INC (US) | 2013-05-28 | — | — | US | disclosed |
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005433-A1 | Fluorinated Compounds | CNR1, NPFFR1, AFF1 | ALDH1A1 1176/4885TSHR 645/4885HPGD 3444/4885 |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | ALDH1A1 1332/4885TSHR 225/4885HPGD 1422/4885 |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | ALDH1A1 1317/4885TSHR 219/4885HPGD 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.